Welcome to Innovacell

Reclaim your health through regenerative medicine

Innovacell is developing a technology platform for the causal treatment of diseases through cell therapy with a focus on fecal and urinary incontinence.

Reclaim your health through regenerative medicine

Introduction

We develop innovative cell therapies for treating fecal and urinary incontinence with the aim of eliminating the cause of these diseases through regeneration. That makes our approach unique. Patients benefit from the minimally invasive administration of cell therapy medicines, which are intended to permanently cure bladder weakness or involuntary stool loss after just one treatment.

We want to make our medicines available to patients as quickly as possible so they can once again live without the restrictions of incontinence.

A comprehensive platform for cell therapy development

Our competencies

Cell production at the highest level

  • Long experience in manufacturing cell products according to the highest international quality standards
  • Proprietary production facility with commercial manufacturing capacity
  • Successfully established processes for producing a wide variety of cell types (muscle cells, connective tissue cells, dendritic cells, hair follicle cells)

Patented technologies

  • Cell isolation method
  • Medical uses of muscle cells
  • Injection systems for precise cell application into the target tissue

Clinical trials of Advanced Therapy Medicinal Products (ATMP)

  • Decades of practice implementing multinational, multicenter clinical studies (phases I, II and III) according to “Good Clinical Practice” (GCP) international guidelines
  • Validated processes for biopsy and cell transport across international borders
  • Successful cooperation with international pharmaceutical regulators such as the EMA, the FDA and the PMDA

Treatment of fecal and urinary incontinence

Our development fields

ICES13

For treating stress urinary incontinence. Cell therapy ICES13, currently in clinical development, is based on the principle of regenerating the sphincter muscle through the use of autologous muscle cells.

Learn more

ICEF15

For treating fecal incontinence (urge incontinence). Treatment with ICEF15 aims at a causal and thus regenerative improvement of the external rectal sphincter. The damaged sphincter’s function will be restored by injecting autologous skeletal muscle cells that have been multiplied in vitro.

Learn more

ICEF16

For treating fecal incontinence (passive incontinence). Cell therapies with autologous muscle cells have the potential to be a promising, safe and effective treatment method for passive incontinence. The damaged, smooth sphincter muscle responsible for passive incontinence is treated with ICEF16.

Learn more

Development, manufacturing, analysis

Our services

Contract Research and Developement

Competent solutions for your research and development projects.

Contract Manufacturing

ATMP production at the highest level.

Contract Analysis

Contract analyses of ATMPs as well as microbiological tests.

Partnerships are added value

Our partners

Univ. Prof. Dr. Sébastien Couillard-Després

Director of the Institute of Experimental Neuroregeneration at Paracelsus Medical Private University

“Our research cooperation with Innovacell has been fruitful for many years. We appreciate the continuous interest of Innovacell in partnering with Universities for translational research projects, which fulfill both academic and industrial interests.”

Contact us

We are always available for contact inquiries and will try to answer your inquiries as quickly as possible.